Skip to search formSkip to main contentSkip to account menu

PF-04937319

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Efficacy and safety of glucokinase activators for type 2 diabetes mellitus: A systematic review
Glucokinase activators (GKAs) are newly drug class proposed for diabetes treatment. This systematic review aimed to assess the… 
2019
2019
A novel Css-MRTpo approach to simulate oral plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite in humans using…
Abstract A Css-MRTpo superposition method was devised to predict (retrospectively) oral plasma concentration–time profiles of PF… 
2017
2017
Simulation of human plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi…
Abstract 1. The partial glucokinase activator N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy… 
2017
2017
Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus
Glucokinase is one of the promising targets for glucose-lowering agents, and the development of GK activators are now considered… 
2016
2016
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF‐04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin—A Randomized, Crossover, Active…
Glucokinase enhances glucose conversion to glucose‐6‐phosphate, causing glucose‐stimulated insulin secretion from pancreatic… 
2015
2015
Two dose‐ranging studies with PF‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes
To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF‐04937319, as add‐on… 
2014
2014
Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator
The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl… 
2014
2014
The Relationship of Glucokinase Activator–induced Hypoglycemia with Arteriopathy, Neuronal Necrosis, and Peripheral Neuropathy in Nonclinical Studies
Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License